{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032947","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-08-14T12:00:39+00:00","discovered_at":"2026-08-14T12:05:01.402530+00:00","generated_at":"2026-08-14T12:05:56.934037+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"PDS Biotech shareholders approve doubling authorized shares to 300M; reelect two directors","bullets":["Shareholders approved amendment increasing authorized common stock from 150M to 300M shares (19.9M for, 11.5M against).","Kamil Ali-Jackson and Ilian Iliev elected as Class B directors; each received ~9M votes for.","KPMG US LLP ratified as independent auditor for FY2026 (30.4M for).","Non-binding say-on-pay approved (7.2M for, 4.0M against, 19.3M broker non-votes).","Quorum of 56.6% (31.6M of 55.8M shares) represented at meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032947","json":"https://secwatch.observer/filing/0001140361-26-032947.json","markdown":"https://secwatch.observer/filing/0001140361-26-032947.md","text":"https://secwatch.observer/filing/0001140361-26-032947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032947/0001140361-26-032947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032947/ef20080184_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:05:56.934037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}